Journal Article (Erratum/Correction)

DKFZ-2024-01494

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.

Zhang, Y. (First author)DKFZ* ; Liu, L.DKFZ* ; Fan, P.DKFZ* ; Bauer, N.DKFZ* ; Gladkich, J.DKFZ* ; Ryschich, E. ; Bazhin, A. V. ; Giese, N. A. ; Strobel, O. ; Hackert, T. ; Hinz, U. ; Gross, M. W.DKFZ* ; Fortunato, F. ; Herr, I. (Last author)DKFZ*

2024
Impact Journals LLC [Erscheinungsort nicht ermittelbar]

This record in other databases:  

Please use a persistent id in citations: doi:10.18632/oncotarget.28527

Keyword(s): Humans (MeSH) ; Gemcitabine (MeSH) ; Deoxycytidine: analogs & derivatives (MeSH) ; Deoxycytidine: pharmacology (MeSH) ; Deoxycytidine: therapeutic use (MeSH) ; Pancreatic Neoplasms: drug therapy (MeSH) ; Pancreatic Neoplasms: pathology (MeSH) ; Pancreatic Neoplasms: metabolism (MeSH) ; Drug Resistance, Neoplasm: drug effects (MeSH) ; Aspirin: pharmacology (MeSH) ; Aspirin: therapeutic use (MeSH) ; Neoplastic Stem Cells: drug effects (MeSH) ; Neoplastic Stem Cells: pathology (MeSH) ; Neoplastic Stem Cells: metabolism (MeSH) ; Antimetabolites, Antineoplastic: pharmacology (MeSH) ; Gemcitabine ; Deoxycytidine ; Aspirin ; Antimetabolites, Antineoplastic

Note: Original article: Oncotarget. 2015; 6:9999–10015. https://doi.org/10.18632/oncotarget.3171

---

Contributing Institute(s):

1. Molekulare Onkochirurgie (G403)

Research Program(s):

1. 319H - Addenda (POF4-319H) (POF4-319H)

Appears in the scientific report 2024

---

Database coverage:
; PubMed Central ; SCOPUS

---